Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer

NCT02022852 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Capecitabine
DRUG: XELOX

Sponsor

Harbin Medical University